Tibremciclib Tartrate

酒石酸泰瑞西利

Report date: 2026/01/27 17:15:56
NME

Base Information

Drug NameTibremciclib Tartrate
Drug Alias Name酒石酸泰贝西利Tibremciclib康美纳BPI-16350
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/06/30
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A